Oral chondroitin sulfate and prebiotics for treating dog inflammatory

Abstract

BACKGROUND: Canine inflammatory bowel disease (IBD) is a chronic enteropathy of unknown etiology, although microbiome dysbiosis, genetic susceptibility, and dietary and/or environmental factors are hypothesized to be involved in its pathogenesis. Since some of the current therapies are associated with severe side effects, novel therapeutic modalities are needed. A new oral supplement for long-term management of canine IBD containing chondroitin sulfate (CS) and prebiotics (resistant starch, &#x3b2;-glucans and mannaoligosaccharides) was developed to target intestinal inflammation and oxidative stress, and restore normobiosis, without exhibiting any side effects. This double-blinded, randomized, placebo-controlled trial in dogs with IBD aims to evaluate the effects of 180&#xa0;days administration of this supplement together with a hydrolyzed diet on clinical signs, intestinal histology, gut microbiota, and serum biomarkers of inflammation and oxidative stress. RESULTS: Twenty-seven client-owned biopsy-confirmed IBD dogs were included in the study, switched to the same hydrolyzed diet and classified into one of two groups: supplement and placebo. Initially, there were no significant differences between groups (p&#x2009;>&#x2009;0.05) for any of the studied parameters. Final data analysis (supplement: n&#x2009;=&#x2009;9; placebo: n&#x2009;=&#x2009;10) showed a significant decrease in canine IBD activity index (CIBDAI) score in both groups after treatment (p&#x2009;<&#x2009;0.001). After treatment, a significant decrease (1.53-fold; p&#x2009;<&#x2009;0.01) in histologic score was seen only in the supplement group. When groups were compared, the supplement group showed significantly higher serum cholesterol (p&#x2009;<&#x2009;0.05) and paraoxonase-1 (PON1) levels after 60&#xa0;days of treatment (p&#x2009;<&#x2009;0.01), and the placebo group showed significantly reduced serum total antioxidant capacity (TAC) levels after 120&#xa0;days (p&#x2009;<&#x2009;0.05). No significant differences were found between groups at any time point for CIBDAI, WSAVA histologic score and fecal microbiota evaluated by PCR-restriction fragment length polymorphism (PCR-RFLP). No side effects were reported in any group. CONCLUSIONS: The combined administration of the supplement with hydrolyzed diet over 180&#xa0;days was safe and induced improvements in selected serum biomarkers, possibly suggesting a reduction in disease activity. This study was likely underpowered, therefore larger studies are warranted in order to demonstrate a supplemental effect to dietary treatment of this supplement on intestinal histology and CIBDAI.